USA flag logo/image

An Official Website of the United States Government

Company Information:

Company Name:
APATH, LLC
Address:
APATH, LLC
893 N. WARSON RD.
SAINT LOUIS, MO 63141
Phone:
N/A
URL:
N/A
EIN:
431828778
DUNS:
75127220
Number of Employees:
N/A
Woman-Owned?:
No
Minority-Owned?:
No
HUBZone-Owned?:
No

Commercialization:

Has been acquired/merged with?:
N/A
Has had Spin-off?:
N/A
Has Had IPO?:
N/A
Year of IPO:
N/A
Has Patents?:
N/A
Number of Patents:
N/A
Total Sales to Date $:
$ 0.00
Total Investment to Date $
$ 0.00
POC Title:
N/A
POC Name:
N/A
POC Phone:
N/A
POC Email:
N/A
Narrative:
N/A

Award Totals:

Program/Phase Award Amount ($) Number of Awards
SBIR Phase I $1,954,965.00 14
SBIR Phase II $3,919,668.00 6
STTR Phase I $741,038.00 1

Award List:

HEPATITIS C VIRUS RNA QUANTITATION USING THE 3' NTR

Award Year / Program / Phase:
1999 / SBIR / Phase I
Award Amount:
$109,410.00
Agency:
HHS
Principal Investigator:
Paul D. Olivo
Abstract:
Not Available In the 21st century the United States will face military scenarios requiring weapons with unprecedented capabilities including nonlethal force projection and potentially countering releases of weapons of mass destruction (WMD). High Power Acoustic Beam (HPAB) technology (i.e., weapons… More

N/A

Award Year / Program / Phase:
2000 / SBIR / Phase I
Award Amount:
$99,240.00
Agency:
HHS
Principal Investigator:
Paul D. Olivo
Abstract:
N/a

Hepatitis C Virus RNA Quantitation Using The 3'NTR

Award Year / Program / Phase:
2001 / SBIR / Phase I
Award Amount:
$0.00
Agency:
HHS
Principal Investigator:
Paul D. Olivo
Abstract:
DESCRIPTION (provided by applicant):The goal of this proposal is to establish the value of the 3' noncoding region (NTR) of hepatitis C virus ((HCV genome as an amplification target in a viral load assay. HCV is the most prevalent chronic bloodborne infection in the U.S.… More

Hepatitis C Virus RNA Quantitation Using The 3'NTR

Award Year / Program / Phase:
2001 / SBIR / Phase II
Award Amount:
$378,638.00
Agency:
HHS
Principal Investigator:
Paul D. Olivo
Abstract:
DESCRIPTION (provided by applicant):The goal of this proposal is to establish the value of the 3' noncoding region (NTR) of hepatitis C virus ((HCV genome as an amplification target in a viral load assay. HCV is the most prevalent chronic bloodborne infection in the U.S.… More

Antiviral Screening Assays Based on HCV Replicons

Award Year / Program / Phase:
2001 / SBIR / Phase I
Award Amount:
$99,395.00
Agency:
HHS
Principal Investigator:
Paul D. Olivo
Abstract:
DESCRIPTION (provided by applicant): Identification of a well-defined and robust cell-culture system for hepatitis C virus (HCV) is critical for facilitating efforts to identify antivirals against HCV. Apath, LLC proposes to develop a series of cell-based assays for… More

ANTIVIRAL SCREENING AGAINST MULTIPLE VIRUSES

Award Year / Program / Phase:
2002 / SBIR / Phase I
Award Amount:
$100,000.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (Provided by applicant): Although cell-based screening has been used successfully throughout the drug-discovery field, it is problematic when screening for antiviral compounds. This is because it requires inoculation of infectious virus onto the cells and the… More

INDICATOR CELLS FOR ANTIVIRAL SCREENING FOR FILOVIRUSES

Award Year / Program / Phase:
2002 / SBIR / Phase I
Award Amount:
$100,000.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): The goal of this proposal is to develop the commercial potential of a cell-based assay to screen for compounds with antiviral activity against filoviruses such as Ebola and Marburg viruses. The basis of this bioassay, which has been prototyped with respiratory… More

ANTIVIRAL SCREENING ASSAYS BASED ON HCV REPLICONS

Award Year / Program / Phase:
2002 / SBIR / Phase II
Award Amount:
$750,000.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (Provided by applicant): Hepatitis C virus (HCV) is the most prevalent chronic blood-borne infection in the U.S and a global health problem. Approximately 4 million individuals in the U.S. and 170 million individuals worldwide are chronically infected. As much as 40 percent of chronic… More

ANTIVIRAL SCREENING ASSAYS BASED ON HCV REPLICONS

Award Year / Program / Phase:
2002 / SBIR / Phase I
Award Amount:
$0.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (Provided by applicant): Hepatitis C virus (HCV) is the most prevalent chronic blood-borne infection in the U.S and a global health problem. Approximately 4 million individuals in the U.S. and 170 million individuals worldwide are chronically infected. As much as 40 percent of chronic… More

Screening for anti-RSV compounds with indicator cells

Award Year / Program / Phase:
2003 / SBIR / Phase I
Award Amount:
$0.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): The goal of this project is to use an infection-independent cell-based assay to identify compounds that inhibit respiratory syncytial virus (RSV). The basis of this bioassay is expression of a reporter gene from an artificial viral genome present within the… More

Screening for anti-RSV compounds with indicator cells

Award Year / Program / Phase:
2003 / SBIR / Phase II
Award Amount:
$733,316.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): The goal of this project is to use an infection-independent cell-based assay to identify compounds that inhibit respiratory syncytial virus (RSV). The basis of this bioassay is expression of a reporter gene from an artificial viral genome present within the… More

Construction of a Respiratory Syncytial Virus Replicon

Award Year / Program / Phase:
2003 / SBIR / Phase I
Award Amount:
$100,000.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): Respiratory syncytial virus (RSV) is the most important respiratory pathogen in infants, especially those born prematurely. It is also an important cause of disease in the elderly and immunosuppressed. There is no vaccine available to protect against RSV and "at… More

Multiplexed Gene Assays by Microtiter Plate Microarrays

Award Year / Program / Phase:
2003 / SBIR / Phase I
Award Amount:
$111,600.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): The drug discovery industry is under increasing pressure to rapidly prioritize compound candidates based on their efficacy and specificity. Although traditional chip based gene expression microarrays can provide significant insights, sample format and throughput… More

Indicator cells for antiviral screening for filoviruses

Award Year / Program / Phase:
2004 / SBIR / Phase II
Award Amount:
$725,891.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): Filoviruses include some of the most notorious human pathogens and cause significant morbidity and mortality due to severe hemorrhagic fever syndromes. Unfortunately, very few therapeutic agents are available to treat infections with these viruses. The goal of… More

Transgenic indicator cells for influenza virus

Award Year / Program / Phase:
2004 / SBIR / Phase I
Award Amount:
$106,026.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): Influenza virus causes a pandemic disease of the respiratory tract that results in significant human morbidity and mortality. Diagnosis of influenza virus infection during the winter months makes up a large component of the clinical virology workload. The goal… More

Molecular tools for Bunyavirus antiviral screening

Award Year / Program / Phase:
2004 / STTR / Phase I
Award Amount:
$741,038.00
Agency:
HHS
Principal Investigator:
Research Institution:
WASHINGTON UNIVERSITY
RI Contact:
N/A
Abstract:
DESCRIPTION (provided by investigator): Several viruses in the family Bunyaviridae are significant human pathogens and potential agents of bioterrorism. Vaccines against some of these viruses do exist, but with the exception of ribavarin, there are no broad-spectrum antiviral compounds capable of… More

Replicon-based screening for inhibitors of alphaviruses

Award Year / Program / Phase:
2004 / SBIR / Phase I
Award Amount:
$958,581.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): The goal in this study is to develop a cell-based assay to screen compounds for antiviral activity against certain members of the Togavirus family. We are particularly targeting the more pathogenic encephalitis-causing viruses from the alphavirus genus, such as… More

Transgenic indicator cells for influenza virus

Award Year / Program / Phase:
2005 / SBIR / Phase II
Award Amount:
$581,898.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): Influenza virus causes a pandemic disease of the respiratory tract that results in significant human morbidity and mortality. Diagnosis of influenza virus infection during the winter months makes up a large component of the clinical virology workload. The goal… More

Filovirus drug discovery using novel combinations of approved drugs

Award Year / Program / Phase:
2005 / SBIR / Phase I
Award Amount:
$70,000.00
Agency / Branch:
DOD / CBD
Principal Investigator:
Paul D. Olivo, President & Chief Scientific Office
Abstract:
The goal of this proposal is find novel combinations of approved drugs for the treatment and/or prevention of infection with filoviruses. Ebola and Marburg viruses, the only filoviruses, cause an acute hemorrhagic fever syndrome which has a high mortality rate and poses a significant bio-terrorism… More

Filovirus drug discovery using novel combinations of approved drugs

Award Year / Program / Phase:
2006 / SBIR / Phase II
Award Amount:
$749,925.00
Agency / Branch:
DOD / CBD
Principal Investigator:
Paul D. Olivo, President & CSO
Abstract:
The goal of this proposal is to find novel combinations of approved drugs for the treatment and/or prevention of infection with filoviruses. Ebola and Marburg viruses, the only filoviruses, cause an acute hemorrhagic fever syndrome which has a high mortality rate and poses a significant… More

The in vitro hepatitis C virus infection system as a drug discovery tool

Award Year / Program / Phase:
2007 / SBIR / Phase I
Award Amount:
$100,713.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): Hepatitis C virus (HCV) infection is a major cause of liver disease throughout the world. Existing therapies are suboptimal and the search for alternative therapies is imperative. Recent years have seen a tremendous inc rease in efforts to identify more effective… More